Clinical Trials on T-lymphoblastic Lymphoma in Poland

Total 820 results

Celgene

Completed

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial (EMERGE)

Mantle Cell Lymphoma

United States, France, Belgium, Austria, Israel, Singapore, Spain, United Kingdom, Hungary, Colombia, Germany, Italy, Turkey, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
Celgene

Completed

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)

Lymphoma, Non-Hodgkin

United States, Belgium, Germany, Japan, Netherlands, France, Sweden, Italy, Spain, Switzerland, United Kingdom, Finland
Bristol-Myers Squibb
Seagen Inc.

Completed

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)

Non-Hodgkin's Disease

United States, France, Canada, United Kingdom, Italy, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Australia, Brazil, Canada, Mexico, New Zealand, Peru
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
University of Texas Southwestern Medical Center

Terminated

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Lymphoma | Leukemia

United States, Canada
Novartis Pharmaceuticals
GlaxoSmithKline

Terminated

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (HOMER)

Non-Hodgkin's Lymphoma

China, United States, Belgium, Czechia, France, Japan, Bulgaria, Canada, Hungary, Peru, Slovakia, South Africa, Ukraine, Korea, Republic of, Puerto Rico, Brazil
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States
Affimed GmbH
Merck Sharp & Dohme LLC; The Leukemia and Lymphoma Society

Completed

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Spain
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Disease, Hodgkin

United States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
SWOG Cancer Research Network
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and...

Active, not recruiting

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Hodgkin Lymphoma | Cardiovascular Disorder | Clonal Hematopoiesis

United States
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)

Non-Hodgkin Lymphoma

United States, Puerto Rico
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma

United States
CytomX Therapeutics

Completed

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

United States, Netherlands, Poland, Spain, Ukraine, United Kingdom
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Virtual Reality Experiences for Anxiety and Pain Control

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Leukemia

United States, Canada, Australia, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia

Leukemia

United States, Canada, Netherlands, Puerto Rico, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Anemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia...

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Mantle Cell Lymphoma | CD20 Positive

United States
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Theradex

Unknown

Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse

Lymphoma

United States, Puerto Rico
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

Lymphoma, Mantle-Cell

United States, China, Spain, Belgium, Canada, Australia, Czechia, Italy, Taiwan, Germany, Japan, New Zealand, United Kingdom, Denmark, Brazil, Israel, France, Netherlands, Korea, Republic of, Poland, Hungary, Austria, Switzerland, Por... and more
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma | Refractory Childhood Hodgkin Lymphoma | Recurrent Childhood Hodgkin Lymphoma

United States, Canada
National Cancer Institute (NCI)

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

United States, Puerto Rico, Canada
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Lymphoma

United States
Novartis Pharmaceuticals

Completed

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Adenocarcinoma | Diffuse Large B Cell Lymphoma | Esophageal Adenocarcinoma | Ovarian Adenocarcinoma | Castration Resistant Prostate Adenocarcinoma | Advanced Well-differentiated Neuroendocrine Tumors

United States
Hoffmann-La Roche

Completed

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Belarus, Poland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Favrille

Terminated

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Suspended

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
Genentech, Inc.
Roche Pharma AG

Completed

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Non-Hodgkin's Lymphoma

United States, Spain, France, Canada, United Kingdom, Austria, Belgium, Czechia, Russian Federation, Italy, Switzerland, Germany, Netherlands, Sweden
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin

United States, Canada
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Melphalan With BBBD in Treating Patients With Brain Malignancies

Lymphoma | Brain and Central Nervous System Tumors | Metastatic Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Medical University of Gdansk

Recruiting

Radiation Free Chemotherapy for Early Hodgkin Lymphoma (RAFTING)

Hodgkin Lymphoma

Italy, Poland, Spain
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Lymphoma

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Disease, Hodgkin

United States, France, Canada, Belgium, Italy
Fred Hutchinson Cancer Center
Global Life Technologies Corp.

Suspended

Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Solid Neoplasm

United States

Clinical Trials on T-lymphoblastic Lymphoma in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations